SCHEMBL9102046

SCHEMBL9102046

NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.69
ADORA3 P0DMS8 1/20 0.66
ALDH1A1 P00352 4/20 0.63
LMNA P02545 3/20 0.63
TSHR P16473 3/20 0.63
BLM P54132 3/20 0.63
THRB P10828 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
ATM Q13315 1/20 0.59
CYP2C9 P11712 3/20 0.59
CYP2C19 P33261 3/20 0.59
CYP3A4 P08684 2/20 0.59
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
HTR1A P08908 1/20 0.59
NFKB1 P19838 1/20 0.59
CNR1 P21554 1/20 0.59
ADRA1A P35348 1/20 0.59
HRH3 Q9Y5N1 3/20 0.55
MEN1 O00255 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11881278 0.99 PPARG (0.67) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL13486392 0.88 PPARG (0.71) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL28407544 0.86 ATM (0.76) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL28905340 0.85 PPARG (0.64) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL23736042 0.85 ADORA3 (0.74) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL28407181 0.84 PPARG (0.76) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL27513111 0.82 PPARG (1.00) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL11874263 0.81 PPARG (0.69) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL12857049 0.81 PPARG (0.62) PPARGADORA3ALDH1A1LMNATSHR
SCHEMBL24162709 0.81 PPARG (0.65) PPARGADORA3ALDH1A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120737058-A Hesperetin derivative, and preparation method and application thereof 江西呐博酒业有限公司 2025-10-03 CN disclosed
CN-111793011-B Styrene sulfone NLRP3 inflammatory corpuscle inhibitor and preparation method and application thereof 山东大学 2021-08-20 CN disclosed
CN-112250604-B Hapten and artificial antigen for broad-spectrum detection of sulfonylurea drugs, antibody and application thereof 华南农业大学 2021-07-20 CN disclosed
CN-112250604-A Hapten and artificial antigen for broad-spectrum detection of sulfonylurea drugs, antibody and application thereof 华南农业大学 2021-01-22 CN disclosed
CN-111793011-A Styrene sulfone NLRP3 inflammatory corpuscle inhibitor and preparation method and application thereof 山东大学 2020-10-20 CN disclosed
US-20090131372-A1 PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES CHEN JAMES M 2009-05-21 US disclosed
US-20090131372-A1 PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES CHEN JAMES M 2009-05-21 US disclosed
US-7407965-B2 Phosphonate analogs for treating metabolic diseases GILEAD SCIENCES, INC. (US) 2008-08-05 US disclosed
US-7407965-B2 Phosphonate analogs for treating metabolic diseases GILEAD SCIENCES, INC. (US) 2008-08-05 US disclosed
US-5576436-A FLUORESCENT LABELED LIGANDS FOR MEASUREMENT OF RECEPTORS PHARMACEUTICAL DISCOVERY CORPORATION (US) 1996-11-19 US disclosed
US-4379785-A Heterocyclic substituted sulfonyl ureas, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1983-04-12 US disclosed
US-4379153-A Benzenesulfonyl ureas, and pharmaceutical preparations HOECHST AKTIENGESELLSCHAFT (DE) 1983-04-05 US disclosed
US-4325963-A ANTIDIABETIC AGENT HOECHST AKTIENGESELLSCHAFT (DE) 1982-04-20 US disclosed
US-4157395-A TREATMENT OF DIABETES HOECHST AKTIENGESELLSCHAFT (DE) 1979-06-05 US disclosed
US-4153710-A HYPOGLYCEMIC AGENTS STAROGARDZKIE ZAKLADY FARMACEUTYCZNE POLFA (PL) 1979-05-08 US disclosed
US-4132795-A Benzenesulfonyl ureas and their use for the treatment of diabetes mellitus HOECHST AKTIENGESELLSCHAFT (DE) 1979-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131372-A1 PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES PHOSPHO1, G6PC1, PC PPARG 314/4885ADORA3 1674/4885ALDH1A1 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.